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Summarv In Sweden. impro%ement in sun-ival rates of patients with cutaneous malignant melanoma has
counteracted the increase in incidence to produce a moderate rise in mortality. Our aim was to determine the
possible impact of drift in diagnostic criteria. earlier diagnosis and changing biological features of the tumours
upon trends in surVival. We studied a stratified sample of 528 patients diagnosed between 1960 and 1984 in a
strictly defined geographical region. No evidence of drift in diagnostic criteria was found. The proportion of
patients with invasion level Clark 11 increased from 3.2% in 1960-64 to 22.5% in 1980-84. the proportion of
thin melanomas ( 0.75 mm) increased from 9.4% to 31.5% and the tumour thickness decreased significantlv
between each 5 year period of diagnosis. These changes are most likely the results of earlier diagnosis.
However, changes in tumour characteristics have occurred. since the proportion of superficially spreading
malignant melanoma increased from 35% in 1960-64 to 51% in 1980-84 and the proportion of acral
lentiginous melanoma decreased from 11% to 2%. The proportion of nodular melanomas remained fairly
constant. The proportion of tumours with lymphocytic reaction did not change. whereas those with histo-
logical regression increased slightly. Proportional hazards analyses showed a significantly lower survival in
patients diagnosed in 1960-64 but no apparent trend after 1965. This finding remained after adjustment for all
studied clinical and histopathological factors which point towards changes in unmeasured biological features
of the disease.
Many studies have reported increasing incidence rates of
malignant melanoma during the last 30-40 years in countries
with white populations (Jensen & Bolander, 1980; Lee, 1985;
Hakulinen et al., 1986; 0sterlind et al., 1986). These trends
should be real since so far no apparent changes have been
revealed in the histopathological criteria for the diagnosis of
malignant melanoma (van der Esch et al., 1991) and the
mortality rates have also increased (Holman et al., 1980;
Venzon & Moolgavkar, 1984; Th6rn et al., 1992). However,
the prognosis has improved in recent years, even after adjust-
ment for temporal changes in distributions by sex, age and
localisation of the primary tumour (Th6rn et al., 1989a).
The reasons for the rising survival rates are incompletely
understood. especially since no therapeutic improvements
have been established. Putative explanations are, firstly, in-
creased public awareness ofmalignant melanoma, which may
entail diagnosis of more tumours early when they are thin
and curable. Secondly, and more speculatively, the biology
and natural history of the disease might change over time,
e.g. because other aetiological factors lead to a biologically
less malignant phenotype. Studies on tumour progression in
malignant melanoma suggest that precursor lesions play an
important role and that the development of the invasive
phenotype involves several steps (Clark et al., 1984). Further,
the metastatic capability may also differ between histo-
logically invasive malignant melanomas (Clark et al., 1989).
Our aim was to determine to what extent trends in survival
are due mainly to drifts in diagnostic criteria, earlier diag-
nosis or changes in histopathological features such as histo-
genetic type or indicators of host defence mechanisms. We
studied a sample from a population-based cohort of patients
diagnosed between 1960 and 1984 with complete follow-up
until 1989.
Patients and methods
The cohort
The Swedish Cancer Registry was created in 1958. All clinic-
ians, pathologists and cytologists must report to the Registry
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any diagnosis of a malignant disease based on examination
of surgically removed tissues or cytological specimens.
biposies or autopsies. Nearly 100% of all cancers are diag-
nosed by one of these procedures, and in 95% of the cases
both the clinician and the pathologist or cytologist notified
the Registry (Mattson & Wallgren, 1984).
Our study was done in seven counties in central Sweden
with approximately 1.8 million inhabitants. The goal was to
draw a random sample of 12 patients from each of 50
subgroups defined by gender, five anatomical locations and
five 5-year time periods of diagnosis from 1960 through 1984.
The anatomical locations were defined as: eyelid and face;
external ear and scalp-neck; trunk; upper extremity; lower
extremity. The grouping of head-neck sites was based on
earlier findings with similar prognoses in these site groups
(Th6rn et al.. 1989b). In total there were 2.093 eligible cases
of malignant melanoma at the selected localisations. During
the first 5 year period there were 192 eligible cases, during
the second period 289 cases, during the third period 391
cases, during the fourth period 543 cases and during the fifth
period 678 cases. Because the total number of patients in
some subgroups was less than 12 during the earliest periods,
there were 570 rather than 600 potentially eligible patients in
the sample.
In 42 patients it was not possible to retrieve the original
slides or paraffin blocks of the tumours. Thus, 528 (92.6%)
of the sampled patients were analysed. Five of them had
another cancer erroneously coded as cutaneous malignant
melanoma. Further, 24 patients (ten men and 14 women)
were excluded because they had tumours classified as 'not
melanoma' in the histopathological review. These lesions
consisted of various benign pigmented tumours and also
malignant skin lesions other than melanoma. The trend
analyses were based on 499 patients (247 men and 252
women). One patient was excluded from the proportional
hazards analysis because of erroneously coded date of death.
In ten patients (five men and five women) analysed separately
the primary tumour was not known to the patient or to the
doctor, most likely because of complete regression of the
primary tumour. The multivariate analyses were based on
476 patients with complete information. All patients were
followed until 31 December 1989, with respect to date and
cause of death, by matching to the National Cause of Death
Registry (Statistics Sweden, 1961-91).
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Clinical data
We abstracted clinical information from the surgeon's and
the pathologist's separate reports to the Cancer Registry. The
following clinical characteristics were recorded: date of diag-
nosis, stage of diagnosis, sex, age, anatomical localisation of
the primary tumour, date of death and cause of death. Until
the end of 1970, the stage of disease was routinely recorded
in the clinician's report as the absence or presence of meta-
stases. In most instances, the location of the metastases was
also speified. From 1971 until the end of 1984, we classified
the stage of the disease according to the clinical data given
by the surgeon on the note of admission to the pathology
department or on the clinician's report to the Registry.
Histopathological data
From the pathology departments - listed on the report to the
Cancer Registry - the original slides and paraffin blocks were
collected along with the pathologist's original record of the
tumour. All histopathological slides were reviewed by the
same pathologist (F.P.). If the orginal sldes were of poor
quality or missing, new paraffin sections were prepared.
When an orinal diagnosis of malignant melanoma was
changed to a benign diagnosis or to another malignant diag-
nosis as well as melanomas with unusual morphological fea-
tures, the paraffin blocks were recut and new slides were
examined. Moreover, another pathologist examined the speci-
men in order to get a second opinion. Whenever a consensus
between the two pathologists was obtained, the diagnosis was
changed accordingly. In a few cases, immunohistopathologi-
cal staining was performed to confirm or reject the diagnosis
of malignant melanoma. We evaluated the following histo-
pathological characteristics: histogenetic type, level of
invasion, tumour thickness, uceration, vascular invasion, his-
tological regression, lymphocytic reaction, pre-existing naevus
and cell type. A detailed description of the histopathological
classification has been reported previously (Th6rn et al.,
1994).
Analysis
Homogeneity tests were used to test for differences in the
distributions of variables between periods of diagnosis. In
some cases the data actually used in the tests do not exactly
agree with those shown in Table II because categories with
small numbers were merged or deleted. A P-value of 5% or
lower was considered as significant.
To increase the power of the analyses the trendwise
development was modelled using logistic regression models
for most of the variables. In addition to variables represent-
ing period of diagnosis, these models also included the
variables sex, age and location. Two basic sets of models
were analysed. In a first analysis, period of diagnosis was
included as a continuous variable. Results are reported as
odds ratios (OR) with 95% confidence intervals (95% CI) per
5 year period of diagnosis. In a second type of model the
variable period of diagnosis was represented by separate
dummy variables. OR and 95% CI for the last 5 year period
of diagnosis compared with the first one are reported. If the
effect of time is basically linear in terms of the log of the
odds ratios, the power ofthe first type ofanalysis is superior.
The purpose of the second type of analysis was to reveal
possible non-linear effects. For the continuous variable
tumour thickness, standard regression models were used with
the dependent variable considered in both original and
logarithmic form.
In order to quantify the effect of period of diagnosis on
survival alone or while simultaneously adjusting for the
effects of other variables, the Cox proportional hazards
model was used (Lawless, 1982). Deaths from malignant
melanoma, coded in the National Cause of Death Registry
(Statistics Sweden, 1961-91) as the underlying cause cons-
tituted the only end point in this analysis. Thus, patients
were censored at the date of death from other causes, other-
wise at 31 December 1989. Survival curves were constructed
by the Kaplan-Meier method (Kaplan & Meier, 1958).
Reskts
Diagnostic criteria
The 24 patients (10 men and 14 women) with tumours
classified in the re-examination as 'not melanoma' were even-
ly spread over the study period. Cases classified as melanoma
in situ, in the re-examination, increased slightly from 2.2% of
the sample in 1960-64 to 6.3% in 1980-84; this difference
was not statistically significant.
Trends in prognosticfactors
In the area of study the total number of patients with a
newly diagnosed malignant melanoma on the selected ana-
tomical sites increased from 192 in 1960-64 to 678 in
1980-84. The stage distribution of the patients by period of
diagnosis is displayed in Table I. The proportion of patients
with clinically localised disease increased from 82.8% in
1960-64 to 98.2% in 1980-84, whereas patients in stage II
decreased proportionally from 15.3% before 1970 to 0.9%
during the period 1980-84.
In our stratified sample the proportion of patients with
superficially spreading melanoma increased from 35.5% to
51.4% [OR 2.16 (95% CI= 1.15-4.04)] during the study
period, whereas no apparent changes were seen for those
with lentigo maligna melanoma or nodular melanoma. How-
ever, since the incidence of malignant melanoma in the
studied population increased, the actual number of patients
with lentigo maligna and nodular melanoma should also
increase. The proportion of patients with acral lentiginous
melanoma decreased from 10.7% to 1.8% [OR 0.15 (0.03-
0.72)1 and the proportion of those with unclassifiable malig-
nant melanoma decreased from 20.4% to 5.4% [OR 0.17
(0.06-0.48)] (Tables II and III).
The proportion of patients with tumours classified as level
of invasion II according to Clark was 3.2% in 1960-64 and
22.5% in 1980-84 [OR 9.12 (2.60-32.0)]; the proportion
with level III and IV rmained fairly constant, whereas those
with level V decreased [OR 0.23 (0.07-0.76)] (Tables II and
HI).
Tumours 0.75 mm increased from 9.4% to 31.5%; those
of intermediate thickness (0.76-2.49 mm) largely did not
change over time, whereas malignant melanoma of 2.50-
3.99 mm decreased during more recent periods. Patients with
thick melanomas (>4.00 mm) constituted a fairly constant
proportion up to 1980, but decreased during the last period
ofdiagnosis (Table II). When tumour thickness was analysed
Table I The stage distribution at diagnosis of malignant melanoma in a population-based
sample of499 patients in Sweden, 1960-84, by period ofdiagnosis
1960-64 1965-69 1970-74 1975-79 1980-84 Total
Stage n % n % n % n % n % n %
I
II
III
77
13
3
82.8 81
14.0 16
3.2 0
83.5 88
16.5 5
0 1
94.7 98
4.2 6
1.1 0
94.2
5.8
0
109 98.2
0.9
0.9
453
41
5
90.8
8.2
1.0
All stages 93 100.0 97 100.0 94 100.0 104 100.0 111 100.0 499 100.0
I, localiseddiscas; II, regional metastases (intransit or lymph nodes); III, distant metastases.TRENDS IN MELANOMA PROGNOSTIC FACTORS 745
Table n The distribution ofhistopathological characteristics ofmalignant melanoma in a population-based sample
of499 patients diagnosed in Sweden, 1960-84, by period of diagnosis
1960-64 1965-69 1970-74 1975- 79 1980-84 Total
n % n % n % n % n % n %
Histogenetic tYpe
Superficially spreading
melanoma
Lentigo maligna melanoma
Nodular melanoma
Acral lentiginous melanoma
Melanoma in situ
Unclassifiable
All types
X: (20) = 44.20, P = 0.001
Level of invasion (Clark)
I
III
Iv IV
Unclassificable
All levels
r. (12) = 31.07. P=0.002
Ulceration
Absent
Present
Unclassifiable
r (4) = 14.91, P = 0.005
Tumour thickness (mm)
<0.75
0.76-1.49
1.50-2.49
2.50-3.99
>4.00
Mean (s.d.)
Median
r (16)=23.66. P=0.10
Vascular invasion
Absent
Suspect
Obvious
x-(4) = 1.09. P= 0.90
Regression
Absent
Slight
Severe
X2 (8) = 14.71, P = 0.07
LymphocYtic reaction
None
Moderate
Abundant
r (8) = 6.08. P = 0.64
Pre-existing naevus
Absent
Present (common)
Present (dysplastic)
x (8) = 14.80, P = 0.06
Epithelioid cells
Absent
Present
x (4) = 1.01, P= 0.90
Spindle cells
Absent
Present
x2(4)= 5.76, P=0.22
33 35.5 37 38.2 45 47.9 59 56.7 57 51.4 231 46.3
5 5.4 6 6.2 11 11.7 5 4.8 10 9.0 37 7.4
24 25.8 33 34.0 24 25.5 25 24.0 29 26.1 135 27.1
10 10.7 7 7.2 4 4.3 6 5.8 2 1.8 29 5.8
2 2.2 4 4.1 4 4.3 6 5.8 7 6.3 23 4.6
19 20.4 10 10.3 6 6.3 3 2.9 6 5.4 44 8.8
93 100.0 97 100.0 94 100.0 104 100.0 111 100.0 499 100.0
2 2.2 4 4.1 4 4.2 6 5.8 7 6.3 23 4.6
3 3.2 14 14.4 23 24.5 16 15.4 25 22.5 81 16.2
25 26.9 35 36.1 30 31.9 39 37.5 29 26.1 158 31.7
41 44.1 31 32.0 28 29.8 34 32.7 44 39.7 178 35.7
12 12.9 8 8.2 6 6.4 7 6.7 4 3.6 37 7.4
10 10.7 5 5.2 3 3.2 2 1.9 2 1.8 22 4.4
93 100.0 97 100.0 94 100.0 104 100.0 111 100.0 499 100.0
41 46.1 40 43.0 54 58.7 59 56.7 74 66.7 268 54.8
47 52.8 52 55.9 36 39.1 42 40.4 37 33.3 214 43.8
1 1.1 1 1.1 2 2.2 3 2.9 0 0 7 1.4
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
8 9.4 17 18.7 23 25.3 24 23.5 34 31.5 106 22.2
12 14.1 12 13.2 12 13.2 18 17.7 17 15.7 71 15.0
15 17.7 17 18.7 19 20.9 16 15.7 17 15.7 84 17.6
25 29.4 17 18.7 12 13.2 15 14.7 16 14.8 85 17.8
25 29.4 28 30.7 25 27.4 29 28.4 24 22.3 131 27.4
3.92 (3.64) 2.99 (2.71) 3.21 (3.61) 2.77 (2.86) 2.56 (2.65) 3.05 (3.12)
3.00 2.40 1.90 1.90 1.80 2.10
85 100.0 91 100.0 91 100.0 102 100.0 108 100.0 477 100.0
75 84.3 81 87.1 80 87.0 86 82.7 95 85.6 417 85.3
11 12.3 10 10.8 8 8.7 11 10.6 13 11.7 53 10.8
3 3.4 2 2.1 4 4.3 7 6.7 3 2.7 19 3.9
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
66 74.2 65 69.9 62 67.4 73 70.2 69 62.2 335 68.5
17 19.1 21 22.6 26 28.3 28 26.9 26 23.4 118 24.1
6 6.7 7 7.5 4 4.3 3 2.9 16 14.4 36 7.4
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
27 30.3 27 29.0 33 35.9 31 29.8 43 38.7 161 32.9
53 59.6 53 57.0 44 47.8 57 54.8 56 50.5 263 53.8
9 10.1 13 14.0 15 16.3 16 15.4 12 10.8 65 13.3
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
82 92.1 78 83.9 69 75.0 82 78.9 92 82.9 403 82.4
7 7.9 9 9.7 12 13.0 15 14.4 13 11.7 56 11.5
0 0 6 6.4 11 12.0 7 6.7 6 5.4 30 6.1
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
69 77.5 73 78.5 76 82.6 82 78.8 86 77.5 386 78.9
20 22.5 20 21.5 16 17.4 22 21.2 25 22.5 103 21.1
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0
62 69.7 70 75.3 67 72.8 87 83.7 83 74.8 369 75.5
27 30.3 23 24.7 25 27.2 17 16.3 28 25.2 120 24.4
89 100.0 93 100.0 92 100.0 104 100.0 111 100.0 489 100.0746 M. THORN et al.
Table IH Regression models of the trendwise development of histopathological characteristics of
malignant melanoma in a population-based sample of 499 patients diagnosed in Sweden, 1960-84, by
period ofdiagnosis. Forall variables except tumourthickness model I shows theodds ratio(OR) and 95%
confidence intervals (95% CI) per 5 year period of diagnosis when period of diagnosis is included as a
continuous variable. Model 2 shows OR and 95% CI for the last period (1980-84) compared with the first
penod (1960-64) when period ofdiagnosis is represented by separate dummy variables. Both models are
adjusted for changes in the distribution by sex, age and localisation ofthe tumour. For the variable tumour
thickness beta parameters are shown
Model I
OR (95% CI)
Model 2
OR (95% CI}
Histogenetic tipe
Superficially spreading melanoma
Lentigo maligna melanoma
Nodular melanoma
Acral lentiginous melanoma
Unclassifiable
Level ofinvasion (Clark)
II
III
IV
V
U'lceration
Present
i'ascular invasion
Present
Regression
Present
L!_mphocYtic reaction
Present
Pre-evisting naevus
Present
Epithelioid cells
Present
Spindle cells
Present
Tumour thickness
Original
Logarithmic
1.30 (1.13-1.49)
1.09 (0.85-1.41)
0.94 (0.82- 1.08)
0.70 (0.53-0.92)
0.59 (0.46-0.76)
1.35 (1.13-1.61)
1.01 (0.88- 1.16)
0.97 (0.85-1.11)
0.73 (0.56-0.94)
0.78 (0.68-0.89)
1.00 (0.84-1.19)
1.14 (0.99-1.31)
0.94 (0.82-1.08)
1.17 (0.98- 1.40)
1.01 (0.86- 1.18)
0.91 (0.78-1.07)
P (95% CI)
-0.29 (-0.49 to -0.09)
-0.134 (-0.205 to -0.063)
2.16 (1.15-4.04)
2.22 (0.65-7.65)
0.94 (0.49-1.80)
0.15 (0.03-0.72)
0.17 (0.06-0.48)
9.12 (2.60-32.0)
0.95 (0.50-1.82)
0.86 (0.48-1.55)
0.23 (0.07-0.76)
0.40 (0.22-0.73)
0.83 (0.37-1.85)
1.99 (1.06-3.73)
0.71 (0.39-1.31)
2.46 (0.96-6.30)
1.00 (0.50-1.98)
0.85 (0.44-1.66)
P (95% CI)
- 1.32 (-2.18 to -0.46)
-0.60 (-0.91 to -0.29)
as a continuous variable an average decrease of 0.29
(0.09-0.49) mm per 5 year period was obtained. During the
last period tumours on average were 1.32 (0.46-2.18) mm
thinner than in 1960-64. Analyses with tumour thickness in
logarithmic form produced qualitatively similar results (Table
III).
The proportion of patients having ulcerated tumours
decreased significantly during the study period from 52.8%
to 33.3% [OR 0.40 (0.22-0.73)], whereas the proportion of
patients whose tumours showed vascular invasion remained
seemingly constant. There was a significant non-linear in-
crease in the proportion of tumours with either slight or
severe regression [OR 1.99 (1.06-3.73)]. No apparent change
was seen for lymphocytic reaction. The presence of naevus
adjacent to the malignant melanoma, either common naevus
or dysplastic naevus, occurred more often during recent years
[OR 2.46 (0.96-6.30)]. No changes in the specific cell type of
the tumours were seen over time (Tables II and III).
Trends in survival
A significant improvement in prognosis took place for
patients with malignant melanoma diagnosed from 1965 and
onwards compared with patients diagnosed in 1960-64
(Figure 1). The overall corrected 5 year survival rate in-
creased from 54% (95% CI = 42-64%) in 1960-64 to 81%
(72-87%) in 1980-84. Similarly, 10 year survival increased
from 43% (31-54%) to 77% (68-84%). These trends were
further quantified in proportional hazards analyses. A uni-
variate model including period of diagnosis only revealed a
significant decrease in relative hazard (RH) for patients diag-
nosed from 1965 onwards compared with those diagnosed in
100
7 5 4
75I'
o<
cn
50
25
0
1960-64
1965-69
1970-74
1975-79
1980-84
5 10
Years
1 2
15 20
Figre I Survival rates in a sample of 498 patients with
cutaneous malignant melanoma diagnosed in Sweden, 1960-84,
and followed until 1989. by period of diagnosis.
1960-64. However, no further significant changes in RH
were seen for patients with malignant melanoma diagnosed
in 1965-69 compared with those diagnosed during more
recent periods. The same pattern with an early significant
decrease in RH was found also when adjustments were made
for temporal changes in the distribution by gender, age and
anatomical site, and also when all studied variables were
included in the multivariate model (Table IV).TRENDS IN MELANOMA PROGNOSTIC FACTORS 747
Table IV Proportional hazards analyses of period of diagnosis as
determinant of survival in a population-based sample of 498 patients
with malignant melanoma diagnosed in Sweden. 1960-84 and followed
until 1989. Relative hazards (with 95% confidence intervals) were
estimated from the folloWing models: (a) univariate, (b) multivariate
model including sex. age and anatomical site of primary tumour; (c)
multivariate model including all variables (476 patients)
Period of MUodel
diagnosis a) (b, (C)
1960-64 1.00 (reference) 1.00 (reference) 1.00 (reference)
1965-69 0.53 (0.34-0.81) 0.46 (0.29-0.72) 0.46 (0.28-0.76)
1970-74 0.40 (0.25-0.66) 0.36 (0.22-0.59) 0.35 (0.20-0.60)
1975-79 0.52 (0.34-0.80) 0.47 (0.31-0.73) 0.54 (0.34-0.88)
1980-84 0.35 (0.21 -0.57) 0.30 (0.18-0.50) 0.41 (0.24-0.70)
The present study was based on a random sample of patients
from a defined geographical region with 1.8 million inhabi-
tants, whereas most other studies (Drzewiecki et al., 1990;
Balch et al.. 1992) evaluated trends in prognostic factors
among patients referred to certain hospitals. Further, the
same pathologist re-examined all the tumours without prior
knowledge of the original pathology report, date of diagnosis
or outcome. In total. 42 patients were missing in our random
sample. Among the missing patients 31.0% died of malignant
melanoma compared with 33.3% in the study sample. The
length of follow-up was similar in these two groups. Thus, it
is unlikely that the missing patients differed from the studied
ones with regard to distribution of prognostic factors. The
design of our study needs to be acknowledged when trends
are interpreted. Sampling was stratified to optimise power
when, for example. survival was analysed separately by
gender or site (Th6rn et al., 1994). As a consequence, sites
where a larger proportion of all tumours occurred will be
relatively under-represented in relation to the total when all
sampled cases are merged together. Hence. trends confined to
- or more pronounced at - these sites will be underestimated
in overall analyses.
The main purpose of the study was to shed light on the
possible causes of the dramatic increase over time in survival
rate among patients with malignant melanoma. In a nation-
wide analysis based on the Swedish Cancer Registry data we
noted a decrease in hazard rate of 64% among men and 71%
among women during the penrod of 1960-82 (Th6rn et al.,
1989a). Although improvement in treatment can be virtually
ruled out as an important cause. several other mechanisms
could operate.
Our study offered some possibilities to assess the genuine
concern that survival trends in malignant melanoma are con-
founded by 'tnrvial non-biological' factors such as relaxed
histopathological criteria, detection of more borderline
lesions owing to increased removal of suspect naevi or im-
proved completeness and specificity in cancer registration; the
mechanisms by which these factors would affect survival are
less clear though. Like previous studies (Philipp et al.. 1987;
van der Esch et al., 1991) we found no evidence of drift over
time in histopathological criteria for invasive malignant
melanoma. Inclusion of melanoma in situ will inflate survival
rates since this disease entity entails no excess mortality
(Th6rn et al., 1994). We have limited power to confirm
statistically the evidence of a weak increase in cancer in situ.
but the proportion of such tumours was too small to explain
the overall trends in survival.
The proportion of patients with clinically localised disease
in our study increased from approximately 83% in 1960-64
to 98% in 1980-84, similar to the increase in overall
incidence of melanoma stage I at the Sydney Melanoma Unit
(Balch et al., 1992) and in Queensland. Australia (Little et
al., 1980). The observed decrease in metastatic disease at
diagnosis from 1970 and onwards partly coincides with the
change in recording practices regarding stage in the Swedish
Cancer Registry. However. in the present study. mis-
classification by stage is unlikely since we reviewed all the
surgical and pathological reports, which in most cases had
information on stage at diagnosis, and if data on stage were
missing more detailed patient records were collected and
checked for stage at diagnosis.
In our study superficially spreading melanoma displayed
the largest proportional increase, similar to findings in the
combined data from Sydney and Alabama (Balch et al.,
1992) and in Scotland (MacKie et al., 1992). In Queensland.
however, the proportion of superfically spreading melanoma
has remained high (Little et al.. 1980). An earlier Swedish
study (Th6rn et al., 1990) showed among men an increase
mainly in the incidence of malignant melanoma located on
the trunk, whereas among women tumours located on the
extremities and trunk increased. In the present study the
increasing superficially spreading melanomas were pre-
dominantly also located on the trunk in men and on the
trunk or extremities in women (data not shown), as noted
also in Scotland (MacKie et al., 1992). However, population-
based case-control studies did not recognise any differences
in risk factors between superficially spreading melanomas
and other histogenetic types (Osterlind et al.. 1988a,b). Con-
ceivably, too small numbers of cases of, for example. nodular
melanoma have been studied to detect such differences.
Like other investigators (Houghton et al.. 1980; Little et
al.. 1980; Shafir et al., 1982; McGregor et al., 1983; Balch et
al., 1992; MacKie et al., 1992) we found that tumour thick-
ness decreased significantly during the period of study. The
mean tumour thickness decreased from 3.92 mm to 2.56 mm
and the median tumour thickness from 3.00 mm to 1.80 mm.
Further, in accordance with one study (Balch et al., 1992) we
detected fewer ulcerated tumours in more recent periods.
Unlike us, Drzewiecki et al. (1990) found an higher propor-
tion of tumours with lymphocytic reaction in recent years.
Further, in our study we did not recognise any changes in
cell type, which was in contrast to the earlier finding of an
increase of malignant melanoma dominated by epitheloid
cells (Drzewiecki et al.. 1990).
In our study cohort, lymphocytic reaction and histological
regression were favourable prognostic signs (Th6rn et al..
1994). The first finding supports other evidence that tumour-
infiltrating lymphocytes may inhibit tumour spread in malig-
nant melanoma (Herberman, 1992). The proportion of
tumours with moderate or abundant lymphocytic reaction
was virtually stable during the period of this study. We found
a slight increase in the proportion of tumours with histo-
logical regression. However, this study provides no strong
support for the hypothesis that host resistance mechanisms.
assessed with the probably crude measures available, can
explain survival trends in malignant melanoma.
There is no obvious explanation for the difference in sur-
vival between the first 5 year period and the other periods.
However, the relatively large proportion of malignant mela-
noma of unclassifiable histogenetic type (20.4%) during
1960-64 as compared with the later time periods may be the
result of less adequate surgery with use of incisional biopsies
or too narrow resection margins during the earliest time
period. The hypothesis that this practice may facilitate
tumour spread and dissemination has, however, not received
any support (Bagley et al., 1981; Lederman et al.. 1985).
In a previous study (Th6rn et al.. 1989a) based on the total
Swedish population we also found significant improvement in
survival of malignant melanoma during more recent time
periods (most marked among men). which was not verified in
the present study because of the relatively small number of
patients. However, the improvement in prognosis for patients
with malignant melanoma diagnosed during 1960-84 should,
at least partly, be caused by earlier diagnosis reflected by
increasing proportions of thinner, less invasive and less
ulcerated tumours during recent years. A strong association
between small tumour thickness and long-term cure is well
established in malignant melanoma (Balch et al.. 1978).
Apart from increasing the chance of cure, diagnosis at an
earlier stage should further inflate the survival curve owing to748 M. THORN et al.
lead time bias in those who ultimately died from the disease.
Although difficult to quantify, the magnitude of this effect is
likely to be small. The large increase in superficially spread-
ing melanoma, the proportional decrease in acral lentiginous
melanoma and possibly the early improvement in survival
unexplained by studied clinical and histopathological factors
point towards changes in unmeasured biological features of
the disease.
This study was supported by grants from the Swedish Cancer
Society.
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